Search Within

Nikoletta Lendvai

Formats
  1. Meeting Abstract (71)
  2. Journal Article (33)
  3. Research Letter (2)
Groups
  1. Center for Hematologic Malignancies (106)
  2. Department of Medicine (106)
  3. Hematologic Malignancies, Division of (106)
  4. Myeloma (106)
  5. Hematologic Malignancies Research (77)
  6. Survivorship Research (74)

More Groups

People
  1. Alexander Lesokhin (71)
  2. Hani Hassoun (70)
  3. Heather Landau (68)
  4. Sergio Giralt (67)
  5. David Chung (61)
  6. Carl Landgren (53)

More People

Years
  1. 2022 (1)
  2. 2021 (1)
  3. 2020 (7)
  4. 2019 (7)
  5. 2018 (14)
  6. 2017 (13)

More Years

Publications
  1. Blood (46)
  2. Biology of Blood and Marrow Transplantation (14)
  3. Leukemia and Lymphoma (9)
  4. Bone Marrow Transplantation (6)
  5. Journal of Clinical Oncology (6)
  6. Clinical Lymphoma, Myeloma and Leukemia (5)

More Publications

Publishers
  1. American Society of Hematology (47)
  2. Elsevier Inc. (21)
  3. Nature Publishing Group (10)
  4. Taylor & Francis Group (9)
  5. American Society of Clinical Oncology (6)
  6. Ferrata Storti Foundation (5)

More Publishers

Results (106)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • T-cell depleted allogeneic hematopoietic stem cell transplantation for patients with relapsed, high-risk multiple myeloma permits long-lasting remissions in the absence of graft-versus-host disease
    Meeting Abstract

    Koehne, G.; Devlin, S.; Landau, H.; Hassoun, H.; Lesokhin, A.; Lendvai, N.; Chung, D.; Giralt, S.
    Bone Marrow Transplantation (2015)

    Fulltext@MSK | Save
  • Gain of chromosome 1q portends worse prognosis in multiple myeloma patients treated with novel agent based induction regimens even after autologous transplantation
    Meeting Abstract

    Shah, G. L.; Landry, C.; Londono, D.; Devlin, S.; Kosuri, S.; Lesokhin, A. M.; Lendvai, N.; Hassoun, H.; Chung, D. J.; Koehne, G.; more...
    Biology of Blood and Marrow Transplantation (2015)

    Fulltext@MSK | Save
  • A phase lb dose escalation trial of SAR650984 (Anti-CD-38 mAb) in combination with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma
    Meeting Abstract

    Martin, T. G.; Hsu, K.; Charpentier, E.; Vij, R.; Baz, R. C.; Benson, D. M.; Lendvai, N.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Interim analysis of a randomized phase II trial comparing continuous lenalidomide and dexamethasone to autologous stem cell transplantation in multiple myeloma patients responsive to lenalidomide and dexamethasone induction
    Meeting Abstract

    Weltz, J. I.; Landau, H.; Lendvai, N.; Chung, D. J.; Lesokhin, A. M.; Devlin, S. M.; Riedel, E.; Woo, K. M.; Stellman, A.; Chimento, D.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Ibrutinib, single agent or in combination with dexamethasone, in patients with relapsed or relapsed/refractory multiple myeloma (MM): Preliminary phase 2 results
    Meeting Abstract

    Vij, R.; Huff, C. A.; Bensinger, W. I.; Siegel, D. S.; Jagannath, S.; Berdeja, J.; Lendvai, N.; Lebovic, D.; Anderson, L. D.; Costello, C. L.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Efficacy and risk factors analysis of upfront autologous stem cell mobilization using plerixafor and granulocyte-colony stimulating factor (GCSF) in patients with multiple myeloma
    Meeting Abstract

    Ogunniyi, A.; Rodriguez, M.; Devlin, S. M.; Adel, N. G.; Landau, H.; Chung, D. J.; Lendvai, N.; Lesokhin, A. M.; Landgren, O.; Giralt, S. A.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • A phase Ib dose escalation trial of SAR650984 (anti-CD-38 mAb) in combination with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma
    Meeting Abstract

    Martin, T. G.; Baz, R.; Benson, D. M.; Lendvai, N.; Campana, F.; Charpentier, E.; Vij, R.
    Blood (2014)

    Fulltext@MSK | Save
  • Greater total dose and duration of treatment with bortezomib are associated with higher incidence of chalazion and other ocular side effects
    Meeting Abstract

    Ganesh, K.; Batlevi, C.; Zhang, Z. G.; Hassoun, H.; Lendvai, N.; Landau, H.; Moskowitz, C. H.; Caron, P.; Motzer, R.; Giralt, S. A.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Recombinant (rec) MAGE-A3 protein immunotherapy and peripheral blood lymphocyte (PBL) reconstitution induce strong antigen-specific humoral and cellular immune responses in patients undergoing autologous stem cell transplantation (ASCT) for consolidation of multiple myeloma (MM)
    Meeting Abstract

    Cohen, A. D.; Lendvai, N.; Gnjatic, S.; Jungbluth, A. A.; Bertolini, S.; Pan, L.; Venhaus, R.; Tsakos, I.; Garcia, K.; Thibodeau, L.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Analysis of VDT-PACE utilization in multiple myeloma patients treated at MSKCC for relapsed disease or cytoreduction and stem cell mobilization after initial induction therapy
    Meeting Abstract

    Beyer, K.; Rosner, S.; Woo, K. M.; Devlin, S. M.; Landau, H.; Hassoun, H.; Lendvai, N.; Chung, D. J.; Adel, N. G.; Puto, M.; more...
    Blood (2014)

    Fulltext@MSK | Save